|
شركة Akero Therapeutics، Inc. (AKRO) تقييم DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Akero Therapeutics, Inc. (AKRO) Bundle
عزز اختياراتك الاستثمارية مع حاسبة Akero Therapeutics ، Inc. (Akro) DCF! استكشاف البيانات المالية الفعلية لـ Apple ، وضبط تنبؤات النمو والنفقات ، ومراقبة على الفور كيف تؤثر هذه التعديلات على القيمة الجوهرية لـ Akero Therapeutics ، Inc. (Akro).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -79.0 | -100.5 | -111.0 | -148.6 | -285.4 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .2 | .2 | .3 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -79.2 | -100.8 | -111.3 | -148.7 | -285.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 268.4 | 188.3 | 351.4 | 550.0 | 743.1 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 3.4 | 6.7 | 8.0 | 7.0 | 9.0 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -79.2 | -100.7 | -108.2 | -148.7 | -285.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -75.7 | -97.2 | -106.7 | -149.6 | -283.4 | -9.0 | .0 | .0 | .0 | .0 |
| WACC, % | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -8.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -9 | |||||||||
| Net Debt | -340 | |||||||||
| Equity Value | 331 | |||||||||
| Diluted Shares Outstanding, MM | 67 | |||||||||
| Equity Value Per Share | 4.93 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to generate various scenarios.
- Real-World Data: Akero Therapeutics’ financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
- Customizable and Professional: A refined Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Comprehensive Financial Data: Gain access to precise pre-loaded historical data and future forecasts for Akero Therapeutics, Inc. (AKRO).
- Adjustable Forecast Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow evaluations.
- User-Friendly Dashboard: Intuitive charts and summaries to help visualize valuation outcomes.
- Suitable for All Levels: Designed with a straightforward structure for investors, CFOs, and consultants alike.
How It Works
- 1. Download the Model: Obtain and open the Excel template featuring Akero Therapeutics, Inc.'s (AKRO) financial data.
- 2. Adjust Key Variables: Modify critical inputs such as revenue growth rates, discount rates, and research & development expenses.
- 3. Analyze Results in Real-Time: The DCF model automatically computes the intrinsic value and net present value (NPV).
- 4. Explore Different Scenarios: Evaluate various projections to understand potential valuation impacts.
- 5. Present with Assurance: Deliver expert valuation analyses to enhance your strategic decisions.
Why Choose This Calculator for Akero Therapeutics, Inc. (AKRO)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters easily to suit your financial analysis.
- Real-Time Adjustments: Observe immediate updates to Akero's valuation as you change inputs.
- Pre-Loaded Data: Comes with Akero’s latest financial metrics for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for making strategic decisions.
Who Should Use This Product?
- Biotech Students: Understand drug development processes and apply your knowledge using real-world data.
- Researchers: Integrate advanced therapeutic models into your studies or publications.
- Investors: Validate your investment hypotheses and evaluate market performance for Akero Therapeutics, Inc. (AKRO).
- Market Analysts: Enhance your analysis with a comprehensive, customizable financial model tailored for biotech firms.
- Healthcare Entrepreneurs: Discover how leading biotech companies like Akero Therapeutics are evaluated and positioned in the market.
What the Template Contains
- Pre-Filled DCF Model: Akero Therapeutics’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Akero Therapeutics’ profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.